Incyte 관리

관리 기준 확인 3/4

Incyte CEO는 Herve Hoppenot, Jan2014 에 임명되었습니다 의 임기는 10.92 년입니다. 총 연간 보상은 $ 16.66M, 7.8% 로 구성됩니다. 7.8% 급여 및 92.2% 보너스(회사 주식 및 옵션 포함). 는 € 24.55M 가치에 해당하는 회사 주식의 0.2% 직접 소유합니다. 24.55M. 경영진과 이사회의 평균 재임 기간은 각각 8.9 년과 7.9 년입니다.

주요 정보

Herve Hoppenot

최고 경영자

US$16.7m

총 보상

CEO 급여 비율	7.8%
CEO 임기	10.9yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	8.9yrs
이사회 평균 재임 기간	7.9yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Herve Hoppenot 의 보수는 Incyte 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	US$32m
Jun 30 2024	n/a	n/a	US$97m
Mar 31 2024	n/a	n/a	US$745m
Dec 31 2023	US$17m	US$1m	US$598m
Sep 30 2023	n/a	n/a	US$425m
Jun 30 2023	n/a	n/a	US$366m
Mar 31 2023	n/a	n/a	US$324m
Dec 31 2022	US$17m	US$1m	US$341m
Sep 30 2022	n/a	n/a	US$876m
Jun 30 2022	n/a	n/a	US$945m
Mar 31 2022	n/a	n/a	US$933m
Dec 31 2021	US$14m	US$1m	US$949m
Sep 30 2021	n/a	n/a	US$535m
Jun 30 2021	n/a	n/a	US$338m
Mar 31 2021	n/a	n/a	US$478m
Dec 31 2020	US$16m	US$1m	-US$296m
Sep 30 2020	n/a	n/a	-US$335m
Jun 30 2020	n/a	n/a	-US$191m
Mar 31 2020	n/a	n/a	-US$376m
Dec 31 2019	US$15m	US$1m	US$447m
Sep 30 2019	n/a	n/a	US$405m
Jun 30 2019	n/a	n/a	US$306m
Mar 31 2019	n/a	n/a	US$253m
Dec 31 2018	US$9m	US$996k	US$109m
Sep 30 2018	n/a	n/a	-US$109m
Jun 30 2018	n/a	n/a	-US$102m
Mar 31 2018	n/a	n/a	-US$167m
Dec 31 2017	US$16m	US$967k	-US$313m

보상 대 시장: Herve 의 총 보상 ($USD 16.66M )은 German 시장( $USD 4.86M ).

보상과 수익: Herve 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Herve Hoppenot (64 yo)

10.9yrs

테뉴어

US$16,659,526

보상

Mr. Herve Hoppenot has been the Chairman of the Board at Incyte Corporation since May 2015 and as its Chief Executive Officer and was President since January 13, 2014 until June 05, 2023. Mr. Hoppenot serv...

리더십 팀

이름	위치	테뉴어	보상	소유권
Herve Hoppenot	CEO & Chairman	10.9yrs	US$16.66m	0.20% € 24.6m
Pablo Cagnoni	President and Head of Research & Development	1.6yrs	US$16.57m	0.00087% € 107.7k
Christiana Stamoulis	Executive VP & CFO	5.8yrs	US$5.08m	0.019% € 2.4m
Barry Flannelly	Executive VP & GM of North America	9.5yrs	US$4.09m	0.0062% € 767.7k
Steven Stein	Executive VP & Chief Medical Officer	9.8yrs	US$5.63m	0.0013% € 164.7k
Thomas Tray	VP of Finance	2.8yrs	데이터 없음	0.0041% € 507.6k
Michael Morrissey	Executive VP & Head of Global Technical Operations	8.9yrs	데이터 없음	0.019% € 2.3m
Ben Strain	Head of Investor Relations	no data	데이터 없음	데이터 없음
Sheila Denton	Executive VP	1.2yrs	데이터 없음	0.0023% € 288.5k
Pamela Murphy	Vice President of Investor Relations & Corporate Communications	no data	데이터 없음	데이터 없음
Paula Swain	Executive Vice President of Human Resources	22.3yrs	US$1.31m	0.030% € 3.7m
Vijay Iyengar	Executive VP of Global Medical Affairs	no data	US$3.30m	0.0013% € 158.5k

8.9yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 관리: ICY 의 관리팀은 노련하고 경험 (평균 재직 기간 8.9 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Herve Hoppenot	CEO & Chairman	10.9yrs	US$16.66m	0.20% € 24.6m
Jean-Jacques Bienaime	Independent Director	9.9yrs	US$478.76k	0.0080% € 995.5k
Julian Baker	Independent Lead Director	23.1yrs	US$512.76k	0.14% € 17.9m
Otis Brawley	Independent Director	3.3yrs	US$454.76k	0.0031% € 378.9k
Jacqualyn Fouse	Independent Director	7.9yrs	US$466.26k	0.0073% € 898.9k
Edmund Harrigan	Independent Director	5yrs	US$482.26k	0.0072% € 894.0k
Katherine High	Independent Director	4.8yrs	US$454.76k	0.0042% € 513.8k
Paul Clancy	Independent Director	9.9yrs	US$479.76k	0.0086% € 1.1m
Susanne Schaffert	Independent Director	2.2yrs	US$444.76k	0.0015% € 185.7k

7.9yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: ICY 의 이사회는 경험(평균 재직 기간 7.9 년)으로 간주됩니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/20 07:58
장 마감 주가	2024/12/20 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Incyte Corporation 55 애널리스트 중 23 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Jasper Hellweg	Argus Research Company
Thomas Russo	Baird
Ishan Majumdar	Baptista Research

Incyte 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Insufficient new directors

Executive VP & Chief Medical Officer recently sold €644k worth of stock

Executive VP of Global Medical Affairs recently sold €1.0m worth of stock

Executive VP & GM of North America recently sold €1.1m worth of stock

Incyte Corporation, Annual General Meeting, Jun 12, 2024

Incyte Corporation Announces Executive Changes, Effective November 1, 2023

Recent updates

Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs

Third quarter 2024 earnings released: EPS: US$0.55 (vs US$0.76 in 3Q 2023)

Incyte Corporation to Report Q3, 2024 Results on Oct 29, 2024

Insufficient new directors

Incyte 's Cdk2 Inhibitor Incb123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma

Executive VP & Chief Medical Officer recently sold €644k worth of stock

Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Second quarter 2024 earnings released: US$2.04 loss per share (vs US$0.91 profit in 2Q 2023)

Executive VP of Global Medical Affairs recently sold €1.0m worth of stock

Incyte Corporation to Report Q2, 2024 Results on Jul 30, 2024

Executive VP & GM of North America recently sold €1.1m worth of stock

Incyte Corporation (NasdaqGS:INCY) acquired Escient Pharmaceuticals, Inc. from a group of shareholders.

Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares.

Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares.

First quarter 2024 earnings released: EPS: US$0.76 (vs US$0.097 in 1Q 2023)

Incyte Corporation, Annual General Meeting, Jun 12, 2024

Incyte Corporation Maintains Earnings Guidance for 2024

Incyte Corporation (NasdaqGS:INCY) entered into a definitive agreement to acquire Escient Pharmaceuticals, Inc. from a group of shareholders for $750 million.

Incyte Corporation to Report Q1, 2024 Results on Apr 30, 2024

Incyte Announces New Results from A Phase 2 Study Evaluating the Efficacy and Safety of Twice-Daily Ruxolitinib Cream 1.5% (Opzelura®) in Adult Patients with Hurley Stage 1 or 2 (Mild-To-Moderate) Hidradenitis Suppurativa (HS)

Incyte Corporation Provides Earnings Guidance for 2024

Full year 2023 earnings released: EPS: US$2.67 (vs US$1.53 in FY 2022)

Incyte Corporation to Report Q4, 2023 Results on Feb 13, 2024

Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Incyte Corporation Provides Earning Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$0.76 (vs US$0.51 in 3Q 2022)

Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis

Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Incyte Corporation to Report Q3, 2023 Results on Oct 31, 2023

Incyte Corporation Announces Executive Changes, Effective November 1, 2023

Executive VP & Chief Medical Officer recently sold €1.2m worth of stock

Incyte Corporation Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$0.91 (vs US$0.73 in 2Q 2022)

Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Incyte Corporation to Report Q2, 2023 Final Results on Aug 01, 2023

Incyte Corporation Appoints Pablo J. Cagnoni, M.D. as President and Head of Research & Development, Effective June 5, 2023

First quarter 2023 earnings released: EPS: US$0.097 (vs US$0.17 in 1Q 2022)

Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa

Incyte Corporation Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: EPS: US$1.53 (vs US$4.30 in FY 2021)

Incyte Corporation to Report Q4, 2022 Results on Feb 07, 2023

Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

Third quarter 2022 earnings released: EPS: US$0.51 (vs US$0.82 in 3Q 2021)

Incyte Corporation Announces Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine

Incyte Corporation to Report Q3, 2022 Results on Nov 01, 2022

Incyte Announces the Appointment of Susanne Schaffert as New Member of Its Board of Directors

Incyte Corporation (NasdaqGS:INCY) entered into an agreement to acquire Villaris Therapeutics, Inc. from Medicxi Ventures (UK) LLP and others for $1.4 billion.

Incyte Corporation Announces FDA Approval Of Pemazyre® (Pemigatinib) As The First And Only Targeted Treatment For Myeloid/Lymphoid Neoplasms (MLNs) With FGFR1 Rearrangement

Second quarter 2022 earnings released: EPS: US$0.73 (vs US$0.68 in 2Q 2021)

Incyte Corporation Reaffirms Revenue Guidance for the Full Year 2022

Incyte Corporation Announces U.S. FDA Approval of Opzelura Cream for the Treatment of Vitiligo

Incyte Corporation to Report Q2, 2022 Results on Aug 02, 2022

FDA Approves Eli Lilly and Company and Incyte's OLUMIANT® (baricitinib) as First and Only Systemic Medicine for Adults with Severe Alopecia Areata

Chmp Recommends Approval of Eli Lilly and Company and Incyte's Olumiant® (Baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (Aa)

FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19

Incyte Announces European Commission Approval of Jakavi (Ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease

First quarter 2022 earnings released: EPS: US$0.17 (vs US$0.24 in 1Q 2021)

Incyte Corporation, Annual General Meeting, Jun 15, 2022

Incyte Announces Positive Committee for Medicinal Products Opinion for Capmatinib (Tabrecta®) for the Treatment of Metex14 Advanced Non-Small Cell Lung Cancer

Incyte Corporation to Report Q1, 2022 Results on May 03, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Incyte Corporation Provides Revenue Guidance for the Full Year 2022

Incyte Announces Acceptance and Priority Review of SNDA for Ruxolitinib Cream (Opzelura) as a Treatment for Patients with Vitiligo

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Third quarter 2021 earnings released: EPS US$0.82 (vs US$0.069 loss in 3Q 2020)

Incyte Corporation (NasdaqGS:INCY) entered into stock purchase agreement to acquire 2.92% Syndax Pharmaceuticals, Inc. (NasdaqGS : SNDX) for $35 million.